Journal: Morbidity and Mortality Weekly Report

Article Title: Potential Confounding of Diagnosis of Rabies in Patients with Recent Receipt of Intravenous Immune Globulin

doi: 10.15585/mmwr.mm6705a3

Figure Lengend Snippet: Timeline of events for a patient with autoimmune encephalitis who met Council of State and Territorial Epidemiologists criteria for diagnosis of human rabies and had recently received intravenous immune globulin Abbreviations: CSF = cerebrospinal fluid; IgG = immunoglobulin G; IgM = immunoglobulin M; IVIG = intravenous immune globulin; RLNA = Rabies lyssavirus neutralizing antibody. * By number of days after illness onset.

Article Snippet: IVIG (Privigen [CSL Behring, King of Prussia, Pennsylvania]) was available from two lots received by one of these eight patients.

Techniques: Biomarker Discovery

Journal: Morbidity and Mortality Weekly Report

Article Title: Potential Confounding of Diagnosis of Rabies in Patients with Recent Receipt of Intravenous Immune Globulin

doi: 10.15585/mmwr.mm6705a3

Figure Lengend Snippet: Characteristics and laboratory findings of unvaccinated patients in whom Rabies lyssavirus neutralizing antibodies were detected after receiving IVIG — nine states, 2013–2016

Article Snippet: IVIG (Privigen [CSL Behring, King of Prussia, Pennsylvania]) was available from two lots received by one of these eight patients.

Techniques:

Journal: Morbidity and Mortality Weekly Report

Article Title: Potential Confounding of Diagnosis of Rabies in Patients with Recent Receipt of Intravenous Immune Globulin

doi: 10.15585/mmwr.mm6705a3

Figure Lengend Snippet: Timeline of events for a patient with Eastern equine encephalitis virus infection who had no history of rabies vaccination, but in whom Rabies lyssavirus neutralizing antibodies were detected after receiving intravenous immune globulin Abbreviations: CSF = cerebrospinal fluid; IgG = immunoglobulin G; IgM = immunoglobulin M; IVIG = intravenous immune globulin; RLNA = Rabies lyssavirus neutralizing antibody. * By number of days after illness onset.

Article Snippet: IVIG (Privigen [CSL Behring, King of Prussia, Pennsylvania]) was available from two lots received by one of these eight patients.

Techniques: Virus, Infection

Journal: Biodrugs

Article Title: Reduction of Isoagglutinin in Intravenous Immunoglobulin (IVIG) Using Blood Group A- and B-Specific Immunoaffinity Chromatography: Industry-Scale Assessment

doi: 10.1007/s40259-016-0192-3

Figure Lengend Snippet: Original and modified processes for the manufacture of the intravenous immunoglobulin product, Privigen. a When assessing the clearance of immunoglobulin M isoagglutinins by the anion-exchange chromatography and immunoaffinity chromatography steps, the process steps outlined in orange (ethanol- and octanoic acid fractionation) were omitted to minimize the loss of immunoglobulin M, and therefore the loss of the immunoglobulin M isoagglutinins. This was done because the octanoic acid fractionation step is the main elimination step of total immunoglobulin M. The intention was to retain as much immunoglobulin M as possible for the subsequent isoagglutinin removal steps. AIC immunoaffinity chromatography, AIEX anion exchange chromatography, DF diafiltration, UF ultrafitration. Adapted with permission from Hoefferer et al. © 2015 AABB. Hoefferer L, Glauser I, Gaida A, Willimann K, Marques Antunes A, Siani B, et al. Isoagglutinin reduction by a dedicated immunoaffinity chromatography step in the manufacturing process of human immunoglobulin products. Transfusion. 2015;55(Suppl 2):S117–21. doi:10.1111/trf.13088

Article Snippet: To reduce the levels of isoagglutinins in a chromatographically purified IVIG product (Privigen ® , CSL Behring AG, Bern, Switzerland), an immunoaffinity chromatography (IAC) method was developed; this process was implemented on an industrial scale in 2015.

Techniques: Modification, Chromatography, Fractionation, Diafiltration Assay

Journal: Biodrugs

Article Title: Reduction of Isoagglutinin in Intravenous Immunoglobulin (IVIG) Using Blood Group A- and B-Specific Immunoaffinity Chromatography: Industry-Scale Assessment

doi: 10.1007/s40259-016-0192-3

Figure Lengend Snippet: Anti-A and anti-B titers in intravenous immunoglobulin lots produced with the immunoaffinity chromatography step (Privigen) and intravenous immunoglobulin lots produced using Cohn-like fractionation (Sandoglobulin/Carimune), measured by the European Pharmacopoeia direct method. IAC immunoaffinity chromatography, IgG immunoglobulin G, IVIG intravenous immunoglobulin

Article Snippet: To reduce the levels of isoagglutinins in a chromatographically purified IVIG product (Privigen ® , CSL Behring AG, Bern, Switzerland), an immunoaffinity chromatography (IAC) method was developed; this process was implemented on an industrial scale in 2015.

Techniques: Produced, Chromatography, Fractionation

Journal: Biodrugs

Article Title: Reduction of Isoagglutinin in Intravenous Immunoglobulin (IVIG) Using Blood Group A- and B-Specific Immunoaffinity Chromatography: Industry-Scale Assessment

doi: 10.1007/s40259-016-0192-3

Figure Lengend Snippet: Specific antibody concentrations in intravenous immunoglobulin lots produced with and without the immunoaffinity chromatography step and in intermediates (‘feed’ and ‘flow-through’) of immunoaffinity chromatography

Article Snippet: To reduce the levels of isoagglutinins in a chromatographically purified IVIG product (Privigen ® , CSL Behring AG, Bern, Switzerland), an immunoaffinity chromatography (IAC) method was developed; this process was implemented on an industrial scale in 2015.

Techniques: Produced, Chromatography, Concentration Assay

Journal: Biodrugs

Article Title: Reduction of Isoagglutinin in Intravenous Immunoglobulin (IVIG) Using Blood Group A- and B-Specific Immunoaffinity Chromatography: Industry-Scale Assessment

doi: 10.1007/s40259-016-0192-3

Figure Lengend Snippet: Distribution of immunoglobulin G subclasses in intermediates (‘feed’) before immunoaffinity chromatography and final intravenous immunoglobulin product (‘bulk’)

Article Snippet: To reduce the levels of isoagglutinins in a chromatographically purified IVIG product (Privigen ® , CSL Behring AG, Bern, Switzerland), an immunoaffinity chromatography (IAC) method was developed; this process was implemented on an industrial scale in 2015.

Techniques: Chromatography

Journal: Biodrugs

Article Title: Reduction of Isoagglutinin in Intravenous Immunoglobulin (IVIG) Using Blood Group A- and B-Specific Immunoaffinity Chromatography: Industry-Scale Assessment

doi: 10.1007/s40259-016-0192-3

Figure Lengend Snippet:

Article Snippet: To reduce the levels of isoagglutinins in a chromatographically purified IVIG product (Privigen ® , CSL Behring AG, Bern, Switzerland), an immunoaffinity chromatography (IAC) method was developed; this process was implemented on an industrial scale in 2015.

Techniques: Chromatography, Produced

Journal: Frontiers in Immunology

Article Title: Intravenous immunoglobulins for the treatment of prolonged COVID-19 in immunocompromised patients: a brief report

doi: 10.3389/fimmu.2024.1399180

Figure Lengend Snippet: Characteristics of adult immunocompromised patients with B-cell depletion and Sars-Cov2 infection treated by intravenous immunoglobulins.

Article Snippet: The IVIg infusion (CSL Behring Company, Privigen ® ) was administered 3.5 weeks (median) after positive Sars-Cov-2 PCR without any corticosteroids or antiviral treatment.

Techniques: Infection

Journal: Frontiers in Immunology

Article Title: Intravenous immunoglobulins for the treatment of prolonged COVID-19 in immunocompromised patients: a brief report

doi: 10.3389/fimmu.2024.1399180

Figure Lengend Snippet: Comparison of patients treated with IVIg or convalescent plasma for prolonged COVID-19.

Article Snippet: The IVIg infusion (CSL Behring Company, Privigen ® ) was administered 3.5 weeks (median) after positive Sars-Cov-2 PCR without any corticosteroids or antiviral treatment.

Techniques: Comparison, Clinical Proteomics

Journal: PLoS ONE

Article Title: Intravenous Immunglobulin Binds Beta Amyloid and Modifies Its Aggregation, Neurotoxicity and Microglial Phagocytosis In Vitro

doi: 10.1371/journal.pone.0063162

Figure Lengend Snippet: Determination of specific binding to Aβ42 oligomers by ELISA (A and B) and real-time binding by BioLayer Interferometry (C). A Privigen, pAbs-Aβ and 6E10 showed different binding activities to the Aβ42 oligomer-coated plate, with 6E10 mAb exhibiting the strongest binding followed by pAbs-Aβ and Privigen. Privigen Fc fragment showed no binding to Aβ42 oligomers. B A competition ELISA showed that the binding of Privigen, pAbs-Aβ and 6E10 could be competed by pre-incubation with Aβ42, thereby confirming specificity to Aβ42 oligomers. C BioLayer Interferometry (Octet System). Binding curves of pAbs-Aβ, 6E10 and Privigen Fc fragment on monomeric biotinylated Aβ. measured at 133 nM. In an independent experiment, the apparent K D value for the pAbs-Aβ was calculated to be 1.5*10 −7 ±1.8*10 −8 M and 2.1*10 −8 ±1.3*10 −9 M for 6E10. Privigen Fc showed no binding to the Biosensor tip.

Article Snippet: For all assays in this study the IVIG product Privigen® 10% (CSL Behring AG, Bern, Switzerland) was used.

Techniques: Binding Assay, Enzyme-linked Immunosorbent Assay, Incubation

Journal: PLoS ONE

Article Title: Intravenous Immunglobulin Binds Beta Amyloid and Modifies Its Aggregation, Neurotoxicity and Microglial Phagocytosis In Vitro

doi: 10.1371/journal.pone.0063162

Figure Lengend Snippet: Thioflavin T assay showing aggregation kinetics of recombinant Aβ42 (5 µM) alone or co-incubated with either A Privigen, Privigen F(ab′) 2 fragment, and Privigen Fc fragment at 100 µM or with B Privigen, pAbs-Aβ and 6E10 at 1 µM. Recombinant Aβ42 was incubated with various compounds at 100 µM C or 1 µM D and Thioflavin T fluorescence was measured at t = 12 h. Aβ aggregation was significantly decreased by incubation with Privigen and Privigen F(ab) 2 at 100 µM and pAbs-Aβ and 6E10 at 1 µM but not with Privigen Fc at 100 µM (* p<0.05; ** p<0.005).

Article Snippet: For all assays in this study the IVIG product Privigen® 10% (CSL Behring AG, Bern, Switzerland) was used.

Techniques: ThT Assay, Recombinant, Incubation, Fluorescence

Journal: PLoS ONE

Article Title: Intravenous Immunglobulin Binds Beta Amyloid and Modifies Its Aggregation, Neurotoxicity and Microglial Phagocytosis In Vitro

doi: 10.1371/journal.pone.0063162

Figure Lengend Snippet: A and B SH-SY5Y cells were treated with 10 µM monomeric Aβ42 alone or co-incubated with A Privigen, Privigen Fc fragment and Privigen F(ab′) 2 fragment at 100 µM, or with B Privigen, pAbs-Aβ and 6E10 at 1 µM. Cell death was measured by LDH release, normalized to Aβ and expressed in percent. Aβ-mediated neurotoxicity was significantly reduced by Privigen and Privigen F(ab′) 2 fragment at 100 µM (A) and by pAbs-Aβ and 6E10 at 1 µM (B) but not by Privigen Fc fragment at 100 µM (A) and Privigen at 1 µM (B) (** p<0.005). C to E Staining of rat primary cortical neurons (DIV5) after treatment with C 10 µM monomeric Aβ alone or co-incubated with D Privigen (45 µM) or E pAbs-Aβ (0.5 µM). Confocal images showed that Privigen at 45 µM and pAbs-Aβ at 0.5 µM apparently disrupted the binding of Aβ to the neuronal cell body and dendrites, which resulted in the distribution of Aβ in the medium as immune-complexes. Microtubule-associated protein 2 (green), Aβ42 (red), antibody test substances (blue), immune-complexes (violet). Bar 100 µm.

Article Snippet: For all assays in this study the IVIG product Privigen® 10% (CSL Behring AG, Bern, Switzerland) was used.

Techniques: Incubation, Staining, Binding Assay

Journal: PLoS ONE

Article Title: Intravenous Immunglobulin Binds Beta Amyloid and Modifies Its Aggregation, Neurotoxicity and Microglial Phagocytosis In Vitro

doi: 10.1371/journal.pone.0063162

Figure Lengend Snippet: BV-2 cells were treated for 30 min with 2 µM FITC-labelled Aβ fibrils alone or co-incubated with Privigen and Privigen Fc fragment at 45 µM, A and B or with Privigen, pAbs-Aβ and 6E10 at 0.5 µM, C and D . Cytochalasin D was added as an inhibitor for receptor-mediated endocytosis and fucoidan as an inhibitor of scavenger receptor A/B. At 45 µM only Privigen significantly increased the number of phagocytosing cells (A) and the amount of phagocytosed fibrillar Aβ in the FITC-positive cell population (B). At 0.5 µM Privigen slightly whereas pAbs-Aβ and 6E10 significantly increased the number of FITC-positive cells (C). Only with Privigen and pAbs-Aβ the amount of phagocytosed Aβ was significantly increased, whereas 6E10 resulted only in a slightly not statistically significant increased phagocytosis of fibrillar Aβ (D) (** p<0.005).

Article Snippet: For all assays in this study the IVIG product Privigen® 10% (CSL Behring AG, Bern, Switzerland) was used.

Techniques: Incubation

Journal: PLoS ONE

Article Title: Intravenous Immunglobulin Binds Beta Amyloid and Modifies Its Aggregation, Neurotoxicity and Microglial Phagocytosis In Vitro

doi: 10.1371/journal.pone.0063162

Figure Lengend Snippet: BV-2 cells were treated for 4 h with A 2 µM FITC-labelled Aβ fibrils alone or co-incubated with B Privigen (45 µM) and C pAbs-Aβ (0.5 µM), D Privigen (45 µM) and Fucoidan or E Privigen (45 µM)and Blebbistatin. Incubation with Privigen and pAbs-Aβ resulted in increased uptake of FITC-Aβ fibrils and upregulation of CD11b expression Co-incubation with Privigen and Fucoidan did not abolish Aβ phagocytosis and upregulation of CD11b was still detectable. Incubation of Aβ alone or with Fucoidan showed weak uptake of FITC-Aβ into microglia but without upregulation of CD11b expression. The intracellular FITC-Aβ signal was localized in punctate structures that co-localized with CD11b immunoreactivity and LAMP1 immunoreactivity in cells incubated with Privigen and pAbs-Aβ. CD11b (white), LAMP1 (red), FITC-Aβ (green). Bar 50 µm.

Article Snippet: For all assays in this study the IVIG product Privigen® 10% (CSL Behring AG, Bern, Switzerland) was used.

Techniques: Incubation, Expressing

Journal: PLoS ONE

Article Title: Intravenous Immunglobulin Binds Beta Amyloid and Modifies Its Aggregation, Neurotoxicity and Microglial Phagocytosis In Vitro

doi: 10.1371/journal.pone.0063162

Figure Lengend Snippet: LTP assay using mouse brain sections showed that A oligomeric Aβ42 caused an impairment of LTP, untreated slices exhibited normal LTP. B Privigen protected against Aβ42 when applied at a concentration of 0.5 µM. Privigen at 0.25 µM only slightly improved LTP inhibition. Applied alone at 0.5 µM Privigen had no effect on LTP. C Summary of the LTP data 90 min after TBS. ***P≤0.001; compared to Untreated; ##P≤0.01 compared to Aβ42. D Summary of the LTP data 90 min after TBS. Proline did not impair LTP and did not modify the effect of Aβ42 on LTP. ***P≤0.001; compared to Untreated; ##P≤0.01 compared to Aβ42. E and F Representative fEPSP traces showing evoked responses before (black) and 90 minutes after TBS stimulation (red) for E Aβ42 treated slices with fEPSP 90 min after TBS (red) almost as large as before TBS (black) and F Privigen (0.5 µM)+Aβ42 treated slices clearly showing that Privigen rescued the Aβ-mediated LTP impairment, since the evoked response after TBS (red) is nearly twice as large as the fEPSP before TBS (black). Calibration bars are 0.5 mV and 15 ms. The number of slices was n = 6 for each group.

Article Snippet: For all assays in this study the IVIG product Privigen® 10% (CSL Behring AG, Bern, Switzerland) was used.

Techniques: Concentration Assay, Inhibition